Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

790
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
790
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

3.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

729
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
729
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

278
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
278
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

825
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
825
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

227
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
227

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Benchmarking to Evaluate Heart Failure Mortality by Race and Ethnicity in the United States from 2018 to 2023.

Journal of cardiac failure·2026
Same author

Refining the Definition for "Low Risk" in Pulmonary Arterial Hypertension: Time to Reduce Morbidity and Mortality.

JACC. Heart failure·2026
Same author

Sex and Age Specific Genetic Risk Across the Dilated and Arrhythmogenic Cardiomyopathy Spectrum: Insights From the SHaRe Registry.

Journal of the American College of Cardiology·2026
Same author

From Clinical Success to Physiologic Understanding: Disentangling Sotatercept's Effects in PAH.

Journal of the American College of Cardiology·2026
Same author

Compensating Heart Failure Cardiologists: Is the RVU Model the Right Model?

Circulation. Heart failure·2026
Same author

Ventricular tachycardia ablation associated abnormalities on FDG PET/CT in patients with suspected cardiac sarcoidosis.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026

Related Experiment Video

Updated: Jan 22, 2026

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.1K

Identifying Stage D Heart Failure: Data From the Most Recent Registries.

Thomas M Cascino1, Keith D Aaronson1, Garrick C Stewart2

  • 1Frankel Cardiovascular Center, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA.

Current Heart Failure Reports
|June 29, 2019
PubMed
Summary

Recognizing advanced heart failure (HF) early is crucial. Patient profiles from INTERMACS and ongoing studies like REVIVAL aid in managing complex HF care and shared decision-making.

Keywords:
Heart failureMechanical circulatory supportPrognosisRegistriesVentricular assist device

More Related Videos

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.9K
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.3K

Related Experiment Videos

Last Updated: Jan 22, 2026

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.1K
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.9K
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.3K

Area of Science:

  • Cardiology
  • Medical Technology

Background:

  • Mechanical circulatory support has improved heart failure (HF) outcomes.
  • There is growing interest in identifying patients likely to develop refractory HF earlier.

Purpose of the Study:

  • To review the recognition and management of advanced heart failure.
  • To discuss the utility of patient profiles in advanced HF care.

Main Methods:

  • Utilized data from the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS).
  • Extended INTERMACS profiles to advanced HF patients on medical therapy.
  • Incorporated findings from MedaMACS registries and the ROADMAP study.
  • Considered ongoing studies like the Registry for Vital Information for VADs in Ambulatory Life (REVIVAL).

Main Results:

  • INTERMACS patient profiles describe the spectrum of advanced HF.
  • These profiles are applicable to both device and medical therapy for advanced HF.
  • Shared decision-making requires individualized risk-benefit analysis beyond survival.

Conclusions:

  • Patient profiles are valuable tools for managing advanced HF.
  • Future studies will provide further prognostic information for HF progression.
  • Navigating advanced HF care requires comprehensive data and shared decision-making.